+

WO1997000671A2 - Composition utilisee pour la production de systemes finement disperses, et son procede de preparation - Google Patents

Composition utilisee pour la production de systemes finement disperses, et son procede de preparation Download PDF

Info

Publication number
WO1997000671A2
WO1997000671A2 PCT/EP1996/002709 EP9602709W WO9700671A2 WO 1997000671 A2 WO1997000671 A2 WO 1997000671A2 EP 9602709 W EP9602709 W EP 9602709W WO 9700671 A2 WO9700671 A2 WO 9700671A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
composition according
acid
pharmaceutical preparation
finely dispersed
Prior art date
Application number
PCT/EP1996/002709
Other languages
German (de)
English (en)
Other versions
WO1997000671A3 (fr
Inventor
Günther Maierhofer
Pedro Gonzales Ensenat
Original Assignee
Dianorm G. Maierhofer Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dianorm G. Maierhofer Gmbh filed Critical Dianorm G. Maierhofer Gmbh
Publication of WO1997000671A2 publication Critical patent/WO1997000671A2/fr
Publication of WO1997000671A3 publication Critical patent/WO1997000671A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
    • C09K23/14—Derivatives of phosphoric acid
    • D—TEXTILES; PAPER
    • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
    • D06M13/10—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing oxygen
    • D06M13/144—Alcohols; Metal alcoholates
    • D—TEXTILES; PAPER
    • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
    • D06M13/10—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing oxygen
    • D06M13/184—Carboxylic acids; Anhydrides, halides or salts thereof
    • D06M13/207—Substituted carboxylic acids, e.g. by hydroxy or keto groups; Anhydrides, halides or salts thereof
    • D—TEXTILES; PAPER
    • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
    • D06M13/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment
    • D06M13/322—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing nitrogen
    • D06M13/44—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with compounds containing nitrogen containing nitrogen and phosphorus
    • D06M13/453—Phosphates or phosphites containing nitrogen atoms
    • D—TEXTILES; PAPER
    • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06P—DYEING OR PRINTING TEXTILES; DYEING LEATHER, FURS OR SOLID MACROMOLECULAR SUBSTANCES IN ANY FORM
    • D06P1/00—General processes of dyeing or printing textiles, or general processes of dyeing leather, furs, or solid macromolecular substances in any form, classified according to the dyes, pigments, or auxiliary substances employed
    • D06P1/44—General processes of dyeing or printing textiles, or general processes of dyeing leather, furs, or solid macromolecular substances in any form, classified according to the dyes, pigments, or auxiliary substances employed using insoluble pigments or auxiliary substances, e.g. binders
    • D06P1/64—General processes of dyeing or printing textiles, or general processes of dyeing leather, furs, or solid macromolecular substances in any form, classified according to the dyes, pigments, or auxiliary substances employed using insoluble pigments or auxiliary substances, e.g. binders using compositions containing low-molecular-weight organic compounds without sulfate or sulfonate groups
    • D06P1/651—Compounds without nitrogen
    • D06P1/65106—Oxygen-containing compounds
    • D06P1/65118—Compounds containing hydroxyl groups
    • D—TEXTILES; PAPER
    • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06P—DYEING OR PRINTING TEXTILES; DYEING LEATHER, FURS OR SOLID MACROMOLECULAR SUBSTANCES IN ANY FORM
    • D06P1/00—General processes of dyeing or printing textiles, or general processes of dyeing leather, furs, or solid macromolecular substances in any form, classified according to the dyes, pigments, or auxiliary substances employed
    • D06P1/44—General processes of dyeing or printing textiles, or general processes of dyeing leather, furs, or solid macromolecular substances in any form, classified according to the dyes, pigments, or auxiliary substances employed using insoluble pigments or auxiliary substances, e.g. binders
    • D06P1/653—Nitrogen-free carboxylic acids or their salts
    • D—TEXTILES; PAPER
    • D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
    • D06P—DYEING OR PRINTING TEXTILES; DYEING LEATHER, FURS OR SOLID MACROMOLECULAR SUBSTANCES IN ANY FORM
    • D06P1/00—General processes of dyeing or printing textiles, or general processes of dyeing leather, furs, or solid macromolecular substances in any form, classified according to the dyes, pigments, or auxiliary substances employed
    • D06P1/44—General processes of dyeing or printing textiles, or general processes of dyeing leather, furs, or solid macromolecular substances in any form, classified according to the dyes, pigments, or auxiliary substances employed using insoluble pigments or auxiliary substances, e.g. binders
    • D06P1/667—Organo-phosphorus compounds
    • D—TEXTILES; PAPER
    • D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
    • D21H—PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
    • D21H21/00—Non-fibrous material added to the pulp, characterised by its function, form or properties; Paper-impregnating or coating material, characterised by its function, form or properties
    • D21H21/14—Non-fibrous material added to the pulp, characterised by its function, form or properties; Paper-impregnating or coating material, characterised by its function, form or properties characterised by function or properties in or on the paper
    • D21H21/28—Colorants ; Pigments or opacifying agents

Definitions

  • composition for the production of finely dispersed systems and process for their production
  • the present invention relates to a new composition which is particularly suitable for the production of finely dispersed systems, and to a process for their production and their use.
  • Self-functionality i.e. The biological effect of the finely dispersed systems, without containing an active ingredient, has so far been given no importance and has therefore not been investigated.
  • Liquid systems are understood to mean those with a viscosity of 0.9 to 100 mPa 's.
  • the present invention is therefore based on the technical problem of specifying a composition which the manufacturers The provision of long-term stable finely dispersed systems is made possible, the composition at the same time having its own functionality, that is to say having cosmetic or therapeutic properties, without containing other conventional pharmaceutical or cosmetic active ingredients.
  • composition comprising the following components:
  • Nanodisperse lipid / water formulations preferably nanoemulsions, nano-colloids and liposomes, which are stable over a long period of time and have their own functional effectiveness in vivo and in vitro, can be prepared in a simple manner from commercially available devices from the composition mentioned. in particular in the cosmetic and pharmaceutical sector.
  • the composition can be easily loaded with various active ingredients, the composition giving the active ingredients increased stability and effectiveness.
  • the phospholipid of the composition is preferably a phosphatidylcholine of pharmaceutical quality, the aliphatic residues of the phospholipid preferably comprising 12-22 carbon atoms with up to 4 cis double bonds, unbranched aliphatic residues being particularly preferred.
  • a phospholipid in which the aliphatic radicals comprise 16-20 C atoms and a maximum of 3 cis double bonds is particularly preferred, as in natural vegetable lecithins, for example soybean lecithin, the aliphatic radicals R 1 and R 2 being the same or different Number of C- Can have atoms.
  • the phospholipid can also be of natural, semi-synthetic or fully synthetic origin.
  • the bile acid and / or its derivatives can also be of natural, semi-synthetic or fully synthetic origin.
  • Preferred derivatives are salts of bile acid, for example sodium salts.
  • Cholic acid, deoxycholic acid, glycolocholic acid, taurocholic acid, taurodeoxycholic acid, ursocholic acid, chenoxycholic acid are particularly preferred as bile acid.
  • Preferred derivatives are sodium cholate, sodium deoxycholate, sodium glycocholate, sodium taurocholate, sodium taurodeoxycholate, sodium urocholate and sodium chenoxycholate.
  • ethanol 96% ethanol according to DAB 10 is preferably used as ethanol.
  • Ethanol appears to be essential for achieving long-term stability of the finely dispersed systems over a period of more than 18 months.
  • composition according to the invention is preferably provided as a concentrate in which the phospholipid is contained in a concentration of 5 to 250 mg / ml, preferably 40 to 200 mg / ml and the bile acid and / or its derivative (s) is (are) contained in a molar ratio of 2 to 10 to 1 (lipid to cholate).
  • Ethanol is preferably contained in a ratio of between 1: 2 and 1: 0.5 to the phospholipid (V / G), particularly preferably in a ratio of 1: 1.
  • the ethanol content in the stated ratio to the phospholipid used gives the composition a particular stability and also facilitates the production process of the finely dispersed systems, and furthermore this ethanol content is of particular advantage for the intended effectiveness.
  • the concentrate according to the invention is diluted for use in a ratio of 1: 1 to 1: 200, preferably 1: 1 to 1:40 and particularly preferably 1: 5 to 1:20.
  • Water or salt solutions preferably those with 0.1 to 0.9% by weight of sodium chloride, serve as the diluent.
  • compositions which contain 100 g of phospholipid, 0.2 g of tocopherol, 100 ml of 96% ethanol and 13.4 g of sodium cholate per liter of aqueous solution.
  • the composition is preferably used as a finely dispersed system based on lipid mixtures, micelles, mixed micelles, reverse micelles, uni-, oligo- or multilamellar liposomes, nanoemulsions, nanoparticles or nanocolloids.
  • Finely disperse systems are understood here to mean systems with particles whose diameter is approximately 4 to 500 nm. The diameter of the particles is preferably less than 250 nm, very particularly preferably less than 100 nm. The vesicular systems have been best studied.
  • the composition preferably contains a pharmaceutical and / or cosmetic auxiliary, but long-term stability of the finely dispersed systems over several years can also be achieved without these auxiliary agents.
  • antioxidants for example, can be added to the composition if an unsaturated phosphatidylcholine is used as the phospholipid. Tocopherol is usually added as an antioxidant.
  • salts in particular table salt or buffer substances
  • cosurfactants such as, for example, polysorbate or free fatty acids, thickening agents and also preservatives are preferred as auxiliaries, as are customarily used in pharmaceuticals and / or cosmetics.
  • composition is particularly suitable for the production of a pharmaceutical preparation.
  • the composition as such has biological activity which makes it appear particularly useful for use in the therapeutic field.
  • the active ingredient-free composition makes it particularly suitable for the treatment of bacterial and viral infections (as well as AIDS), for the treatment of cancer, Alzheimer's disease, Crohn's disease and ulcerative colitis, asthma, bronchitis, high blood pressure and also hypoxia.
  • the pharmaceutical preparation according to the invention has been used effectively for the treatment of skin diseases and the treatment of the dry eye and the dry mouth. When applied topically to the skin and to the eyelids, it was found that non-oily formulations for the therapy of skin allergies and for the therapy of the dry eye were significantly effective.
  • the optional addition of vitamin C also showed an antiviral and anticancerogenic activity.
  • the intrinsic functionality of the systems can be strengthened in a synergistic manner by adding and / or storing active substances.
  • the increase in activity through the combination of the finely dispersed system and the active ingredient is presumably due to the fact that the finely dispersed system disperses the active ingredient particularly finely in vivo in cell membranes and thus increases its effectiveness.
  • the pharmaceutical preparation according to the invention contains vitamin C or one of its derivatives.
  • Vitamin C is usually used in a concentration of 0.0002 to 120 mg / ml.
  • the concentration range is so large because completely different application routes are possible, for example topically on the skin (occlusive, but also only sprayed on), orally, IV, IV, intralymphatic and inhalation, and as a test kit in vitro.
  • the concentration of vitamin C is preferably between 1 and 100 mg / ml.
  • composition is incorporated into gelatin, for example hard or soft gelatin capsules.
  • the finely dispersed system in particular in the form of liposomes, the ATP level in several experimental cell culture systems.
  • the composition can lower the cAMP level of isolated rat cortex.
  • diseases include, for example, cancer and Alzheimer's disease.
  • cancer cells have an elevated cAMP level and that lowering the cAMP level can eliminate the malignant phenotype.
  • Alzheimer's disease it was found in Alzheimer's disease that lowering the ATP level leads to a relief of the symptoms of the disease.
  • the preparation according to the invention shows an increased oxygen consumption and a significant increase in temperature in a lymphocyte culture. Furthermore, it was found that in vitro oxygen radical formation (oxonium ion formation) occurs, the release of such radicals being further increased by the addition of vitamin C.
  • This property of the preparation according to the invention also allows it to be used as an immunostimulating agent.
  • the preparation according to the invention shows a significant dose-dependent toxicity to leukemia cells (HUT78, L578Y), which could be increased synergistically by vitamin C.
  • HUT78, L578Y leukemia cells
  • the Toxicity of the composition decreased significantly. This opens the way for the composition according to the invention for the prophylaxis and / or therapy of cancer diseases (see also Example 6) and for the prophylaxis and / or therapy of monoclonal, polyclonal or malignant gammopathies, primary, secondary or combined immunodeficiency diseases, autoim - to use munopolyendocrinopathies and autoimmune diseases.
  • the autoimmune diseases can be organ-specific, for example pernicious anemia, chronic gastritis, juvenile diabetes mellitus, and non-organ-specific diseases, such as diseases of the rheumatic type (eg rheumatoid arthritis, scleroderma) or mixed - Or transitional forms such as autoimmune haematolytic anemia, primary biliary cirrhosis, chronic aggressive hepatitis, ulcerative colitis, Sjogren's syndrome and multiple sclerosis.
  • diseases of the rheumatic type eg rheumatoid arthritis, scleroderma
  • mixed - Or transitional forms such as autoimmune haematolytic anemia, primary biliary cirrhosis, chronic aggressive hepatitis, ulcerative colitis, Sjogren's syndrome and multiple sclerosis.
  • composition according to the invention is also suitable for the production of cosmetic preparations, such preparations being particularly suitable for "simple" skin protection and normal skin care. Cosmetic preparations are also suitable for incorporation into gelatin.
  • compositions according to the invention can also be added to the composition according to the invention.
  • dyes attached to or embedded in the particles of the finely dispersed system
  • textiles leather or paper can be dyed or conditioned.
  • the composition according to the invention is added to the dialysis liquid usually used in kidney dialyzers.
  • the effectiveness of blood purification and detoxification has been observed to increase significantly. The reason the rapid and effective adsorption of amphiphilic metabolites onto the particles of the finely dispersed system, in particular the liposomes, should be found for this.
  • Finely dispersed systems can be produced from the composition according to the invention by adding mechanical energy, such as, for example, by optimized mixing in static mixers, pressure filtration, stirring, homogenization or filtration.
  • Commercially available devices can be used for this, such as static mixing systems or Gaulin homogenizers or a microfluidizer. If more than 100 mg / ml of oil, based on the composition, is added in these processes, the process leads to nanoemulsions or nanocolloids, and without addition of oils or oil concentrations of ⁇ 30 mg / ml, based on the composition the procedure to liposomes.
  • oils can be used as such oils, e.g. Miglyol, jojoba oil, borage oil, castor oil, safflower oil, paraffin oils etc., and also essential oils such as 01-bas, tea tree oil, peppermint oil etc.
  • the resulting particles have an average diameter of less than 200 nm (measured with a light scattering device Coulter N4SD). Their diameter no longer changes due to the thinning steps. Dilutions 1: 1, 1: 5, 1:10, 1:20, 1:50, 1: 100, 1: 200, 1: 400 were checked.
  • Water-soluble active ingredients are dissolved together with the sodium cholate in the aqueous phase before it is combined with the ethanolic lipid solution.
  • Lipophilic active ingredients are dissolved in the ethanol together with the lipid. Become oils dissolved in the ethanolic lipid solution before combining with the aqueous phase or added to the ready system and stirred with the system a second time.
  • solubility properties of active ingredients to be stored in the finely dispersed system are poor, the solubility can be improved by adding co-surfactants, e.g. Polysorbate 80, Arlasolve, free fatty acid such as oleic acid etc., and / or by small additions of other alcohols, e.g. Isopropanol, glycol or propylene glycol.
  • co-surfactants e.g. Polysorbate 80, Arlasolve, free fatty acid such as oleic acid etc.
  • other alcohols e.g. Isopropanol, glycol or propylene glycol.
  • an active ingredient is to be added to the finely dispersed system, its solubility properties are predissolved in additional ethanol or aqueous phase, added to the finished finely dispersed system and incorporated by stirring.
  • the desired storage can take place in a two-chamber system from which the active substance is mixed with the finely dispersed system only shortly before use.
  • the patient JLSM 47 years old, was diagnosed with duodenal ulcer at the age of 17 years. During a routine check in October 1990, a prepoly ulcer was also found. Both were more or less controlled. Routine control in November 1994 showed the endoscopic biopsy is transformed into a little differentiated carcinoma. A surgical treatment was then recommended and carried out. 15 days before the operation, the patient received 30 ml of liposomes containing ascorbate daily. The tissue removed during the operation was examined histologically. Diagnosis: Ulcer pepticum with fibrinoid necrosis at the base and regenerative changes on the edge. No evidence of atypia, no deterioration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Textile Engineering (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

La composition décrite contient au moins un phospholipide, au moins un acide biliaire et/ou au moins un dérivé d'acide biliaire, de l'éthanol et de l'eau. Cette composition est utilisée pour la production de systèmes finement dispersés qui peuvent être longtemps stockés sans se dégrader. Les systèmes finement dispersés sont particulièrement utiles pour préparer des compositions pharmaceutiques et cosmétiques et présentent une activité biologique même s'ils ne contiennent pas un principe actif pharmaceutique usuel.
PCT/EP1996/002709 1995-06-22 1996-06-21 Composition utilisee pour la production de systemes finement disperses, et son procede de preparation WO1997000671A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19522693.3 1995-06-22
DE19522693A DE19522693A1 (de) 1995-06-22 1995-06-22 Zusammensetzung zur Herstellung feindisperser Systeme und Verfahren zu ihrer Herstellung

Publications (2)

Publication Number Publication Date
WO1997000671A2 true WO1997000671A2 (fr) 1997-01-09
WO1997000671A3 WO1997000671A3 (fr) 1997-02-13

Family

ID=7764997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/002709 WO1997000671A2 (fr) 1995-06-22 1996-06-21 Composition utilisee pour la production de systemes finement disperses, et son procede de preparation

Country Status (2)

Country Link
DE (1) DE19522693A1 (fr)
WO (1) WO1997000671A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001001995A3 (fr) * 1999-07-06 2001-11-15 Nutricology Inc Methode de traitement de l'asthme
CN105203576A (zh) * 2015-09-17 2015-12-30 湖南师范大学 一种定位逆胶束酶体系中自旋探针作用位置的方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2111488B1 (es) * 1996-01-17 1998-11-01 Lucas Meyer S A Utilizacion de composiciones proliposomas en la tintura, blanqueo y suavizado de la industrial textil y procedimiento para la preparacion de banos de tintura a partir de dichas composiciones proliposomas.
DE19722831A1 (de) * 1997-05-30 1998-12-03 Univ Halle Wittenberg Vehikelsysteme für Arzneistoffe
AU8285998A (en) * 1997-07-02 1999-01-25 Sdg, Inc. Targeted liposomal constructs for diagnostic and therapeutic uses
ATE372377T1 (de) * 1998-03-30 2007-09-15 Mibelle Ag Cosmetics Verwendung von nanoemulsionen zur bestimmung der biokompatibilität von lipophilen stoffen im zellkultur-test und dafür geeignete nanoemulsionen
TWI241915B (en) 1998-05-11 2005-10-21 Ciba Sc Holding Ag A method of preparing a pharmaceutical end formulation using a nanodispersion
CZ300773B6 (cs) * 2007-01-25 2009-08-05 Univerzita Pardubice Liposom textilního pomocného prostredku, zpusob jeho prípravy a prípravek jej obsahující

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115313A (en) * 1974-10-08 1978-09-19 Irving Lyon Bile acid emulsions
IL72420A (en) * 1983-07-22 1987-10-30 Hoffmann La Roche Aqueous vitamin e solutions and their manufacture
EP0252004A1 (fr) * 1986-06-26 1988-01-07 Ciba-Geigy Ag Compositions pharmaceutiques pour l'application parentérale
CA1319886C (fr) * 1987-02-03 1993-07-06 Alberto Ferro Solutions de micelles mixtes
CA2033725C (fr) * 1990-01-24 2001-05-29 Folker Pittrof Compositions pharmaceutiques et cosmetiques
CA2139757C (fr) * 1992-07-08 2009-04-14 Gunther Maierhofer Liposomes, methode pour les preparer et leur utilisation pour la preparation de medicaments
DE4306475A1 (de) * 1993-03-02 1994-09-08 Ensenat Pedro Gonzalez Liposomen, enthaltend Chlorhexidindiacetat oder Chlorhexidindigluconat

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001001995A3 (fr) * 1999-07-06 2001-11-15 Nutricology Inc Methode de traitement de l'asthme
CN105203576A (zh) * 2015-09-17 2015-12-30 湖南师范大学 一种定位逆胶束酶体系中自旋探针作用位置的方法

Also Published As

Publication number Publication date
DE19522693A1 (de) 1997-01-02
WO1997000671A3 (fr) 1997-02-13

Similar Documents

Publication Publication Date Title
DE2730570C2 (fr)
DE69218241T2 (de) Arzneistofformulierung zur parenteralen anwendung
DE69806577T2 (de) Antimykotische substanz und kationische tenside enthaltende zusammensetzung
EP0956853B1 (fr) Utilisation des nanodispersions dans des compositions pharmaceutiques
DE69524953T2 (de) Antibakterielle öl-in-wasser-emulsion
DE60115045T2 (de) Verbesserte liposomale camptothecine und deren verwendungen
EP0733372A2 (fr) Base pharmaceutique pour la formulation de nanosuspensions
EP0711557A1 (fr) Base pour formulations pharmaceutiques
DE60105322T2 (de) Wässerige zusammensetzung enthaltend amphotericin b
DD201973A5 (de) Verfahren zur herstellung von liposomalen arzneimitteln
DE69008729T2 (de) Verfahren zur herstellung einer öl-in-wasser-emulsion eines wirkstoffes.
DE3713494A1 (de) Verfahren zur herstellung einer dispersion von lipidkuegelchen in einer waessrigen phase und nach diesem verfahren erhaeltliche dispersionen
DE19810655A1 (de) Arzneimittel mit einem Gehalt an Ciclosporin
EP0707847A1 (fr) Liposomes de kétoprofène
WO1997000671A2 (fr) Composition utilisee pour la production de systemes finement disperses, et son procede de preparation
EP1480620B1 (fr) (ester)-lysolecithines dans des liposomen
DE60011625T2 (de) Cisplatin enthaltende parenterale emulsion
EP1827379B8 (fr) Formulations contenant des alkylphosphocholines faisant intervenir de nouveaux porteurs de charge negatifs
EP0535567B1 (fr) Liposomes contenant des anéstésiques d'inhalation volatiles, leurs préparations et leurs utilisations
EP0470437B1 (fr) Système aqueux de liposomes
WO2001072289A2 (fr) Medicament pour stimuler la leucopoese, pour traiter des affections tumorales et des protozooses, l'acarinose, l'arthropodiase et procedes permettant de le produire
DE19951474A1 (de) Celluloseether stabilisierte Öl-in-Wasser Emulsionen als Träger für homöopatische und pflanzliche Wirkstoffe
WO2003028736A2 (fr) Liposomes a base d'alkylphosphocholine sterilisables a chaud
DE3309076A1 (de) Liposome und verfahren zu ihrer herstellung
DE69307197T2 (de) Verwendung von 24,25-Dihydroxyvitamin-D3 zur Herstellung eines Arzneimittel zur Behandlung der Rachitis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载